FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN ...
BLINCYTO® (blinatumomab) approved by FDA for CD19-positive B-ALL treatment in consolidation phase, showing 58% reduced death risk and superior overall survival versus chemotherapy alone, based on Phase 3 E1910 trial results.
Reference News
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN ...
BLINCYTO® (blinatumomab) approved by FDA for CD19-positive B-ALL treatment in consolidation phase, showing 58% reduced death risk and superior overall survival versus chemotherapy alone, based on Phase 3 E1910 trial results.